12:00 AM
 | 
Nov 19, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

AeroVanc regulatory update

Savara said FDA granted Orphan Drug designation for AeroVanc to treat methicillin-resistant Staphylococcus aureus (MRSA) infection in...

Read the full 61 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >